Paolo Tarantino

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2024
September 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  

Paolo Tarantino
Sep 15, 2024, 08:33 | Drugs
Paolo Tarantino: Some HER2+ tumors melt upon dual anti-HER2 Treatment
Paolo Tarantino shared on X: "Some HER2+ tumors melt upon dual anti-HER2 Treatment; others require…
Sep 14, 2024, 19:28 | Insight
Paolo Tarantino: Are all residual diseases equal?
Paolo Tarantino shared on LinkedIn: “ Patients with residual breast cancer after neoadjuvant treatment harbor…
Sep 14, 2024, 17:15 | Societies
45 Posts not to miss from ESMO24 Day 1
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at…
Sep 14, 2024, 06:35 | Opinion
Paolo Tarantino: Interesting data with TROP2 quantitative continuous scoring to predict Dato-DXd activity in lung cancer
Paolo Tarantino posted the following on X: “Interesting data with TROP2 quantitative continuous scoring (QCS)…
Sep 13, 2024, 07:23 | Blog
Paolo Tarantino: List for the upcoming early-phase ADCs at ESMO24
Paolo Tarantino shared a post by Raffaele Colombo on X, adding: "Terrific list of ADC data to…
Sep 10, 2024, 06:01 | Insight
Paolo Tarantino: A Special Collection for ADCs in Breast Oncology for Nature Portfolio
Paolo Tarantino shared on LinkedIn: "The field of ADCs is still at its dawn. Many…
Sep 7, 2024, 19:36 | Insight
A year of treatment with an ADC has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute shared the following on LinkedIn: “A year of treatment with a medicine…
Sep 7, 2024, 11:16 | Drugs
Paolo Tarantino: Recommended read on adjuvant ribociclib in preparation for the ESMO24
Oncology Brothers shared a post by Paolo Tarantino on X, adding: “Adjuvant abemaciclib preferred for…
Sep 7, 2024, 10:06 | Blog
Is adjuvant ribociclib ready for prime time?
Sarah Sammons shared a post by Paolo Tarantino, on X: "The number needed to treat (NNT) to…
Sep 6, 2024, 11:25 | Insight
Paolo Tarantino: Interesting RWA of outcomes with chemotherapy in HR+/HER2- MBC
Paolo Tarantino shared a post by ESMO Open on X, adding: "Interesting real world analysis…
Sep 5, 2024, 15:22 | Blog
Paolo Tarantino: Looking forward to join the Medscape symposium to review treatment landscape for HR+/HER2- metastatic breast cancer
Paolo Tarantino shared a post on LinkedIn: "Really looking forward to joining this Medscape symposium to…
Sep 4, 2024, 15:08 | Blog
Paolo Tarantino: Top 10 Breast Cancer abstracts from ESMO2024
Paolo Tarantino shared a post on LinkedIn: "Two weeks to ESMO 2024. Multiple important breast…
Sep 4, 2024, 14:21 | Blog
ESMO 2024 Research Fellowship awardees
ESMO - European Society for Medical Oncology shared a post on LinkedIn: "ESMO is pleased…
Aug 18, 2024, 07:29 | Blog,Opinion
Paolo Tarantino: Do all patients with TNBC need 5 neoadjuvant drugs + 1 year of IO?
Paolo Tarantino shared a post on X about recent paper by Marleen Kok et al., titled…
Aug 12, 2024, 14:48 | Blog
Global study on the accuracy of HER2-low diagnoses among 77 pathologists from 14 countries
Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute shared a recent article by Josef…
Aug 9, 2024, 02:21 | Insight
Paolo Tarantino: Interesting sub analysis from the SENOMAC trial
Paolo Tarantino shared on X about a recent paper by Jana de Boniface et al.…
Aug 9, 2024, 02:19 | Blog
Activity of T-DXd in HER2-expressing Biliary Tract Cancer
Paolo Tarantino shared on X: "Activity of T-DXd in HER2-expressing BTC published in Journal of Clinical…
Aug 7, 2024, 16:50 | Blog
The recipients of the 2024 ESMO Society Awards
The 2024 ESMO Society Awards have been announced on 6th August by ESMO. ESMO recently…
Aug 7, 2024, 00:27 | Blog
Paolo Tarantino reflects on the results from DESTINY-CRC02 published in the Lancet Oncology
Paolo Tarantino shared on X: “Results from DESTINY-CRC02 published in the Lancet Oncology. Among patients…
Aug 3, 2024, 07:34 | Blog
Paolo Tarantino: When diagnosing ILD, the radiologist is your best friend
Paolo Tarantino shared on LinkedIn: "When diagnosing Interstitial Lung Disease (ILD), the radiologist is your…
Jul 29, 2024, 11:19 | Insight
Rasha Aboelhassan: We can give TDM1 in stage I HER2 positive breast cancer
Rasha Aboelhassan shared a post on LinkedIn about a recent paper by Paolo Tarantino et al., commenting:…
Jul 25, 2024, 00:29 | Blog
Paolo Tarantino: Thanks to The ASCO Post for featuring my ADC talk at IBC East
Paolo Tarantino shared a post by The ASCO Post, on X, adding: ''Thanks to The ASCO…
Jul 23, 2024, 08:25 | Blog
Paolo Tarantino: HER2: a remarkable story of precision oncology
Paolo Tarantino shared on X: "HER2: a remarkable story of precision oncology. Check this wonderful Nature…
Jul 21, 2024, 09:23 | Blog
Paolo Tarantino: We just see the tip of the iceberg of how ADCs work
Paolo Tarantino shared on X:            . "On my way to…
Jul 20, 2024, 11:01 | Insight
Paolo Tarantino: Thanks to ESMO for featuring our 5-year analysis of the ATEMPT randomized phase 3 trial
Paolo Tarantino shared a post on LinkedIn about a paper titled "Adjuvant Trastuzumab Emtansine Versus…
Jul 19, 2024, 00:40 | Insight
Paolo Tarantino: Wonderful explanation on how T-DXd/Enhertu work for the treatment of breast cancer
Paolo Tarantino shared a post by Liz O'Riordan on X, adding: "Wonderful explanation for patients…
Jul 15, 2024, 04:50 | Insight
Paolo Tarantino: Our article on ADCs is among the top 10 most cited in CA Cancer Journal
Paolo Tarantino, shared a post on LinkedIn about a recent paper titled "Antibody–drug conjugates: Smart…
Jul 14, 2024, 21:42 | Blog
Paolo Tarantino: Stellar Tumor Board session at the Harvard Medical School Breast Course
Paolo Tarantino shared a post on X: ''Stellar Tumor Board session at the Harvard Medical…
Jul 14, 2024, 14:11 | Blog
Stuart Schnitt about the role of Artificial Intelligence in Pathology - Dana-Farber’s Breast Oncology Center
Paolo Tarantino shared a post by Dana-Farber’s Breast Oncology Center on X/Twitter:       …
Jul 14, 2024, 06:24 | Blog
Dr. Paolo Tarantino reviewed key ongoing clinical trials at Harvard Breast Cancer Course - Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X:   . "Dr. Paolo Tarantino reviewed key…
Jul 14, 2024, 02:45 | Blog
Paolo Tarantino: ASCO Post features ATEMPT's 5 year update
Paolo Tarantino shared on X: "Thanks to the ASCO Post for featuring our JCO publication…
Jul 13, 2024, 07:56 | Blog
Oncoinfluencers to Follow on Social Media: Dr. Paolo Tarantino
Our next oncoinfluencer is Dr. Paolo Tarantino. Dr. Tarantino is active on both X/Twitter and…
Jul 12, 2024, 15:51 | Blog
Paolo Tarantino: Discussion on novel treatment strategies for HR+/HER2- MBC
Paolo Tarantino shared on LinkedIn: "f you’re attending ESMO24 Barcelona, make sure to join Dr. Javier…
Jul 10, 2024, 06:36 | Insight
Paolo Tarantino: Intersecting data with the MAT2A inhibitor IDE397 in MTAPdel lung and urothelial cancer
Paolo Tarantino shared a post by Bio Stocks on X, adding: . "Intersecting data with…
Jul 9, 2024, 09:41 | Insight
Rebecca Shatsky: Love my good friend Paolo Tarantino’s explanation of Her2 Ultra Low
Rebecca Shatsky shared a post by Paolo Tarantino on X, adding: “Love my good friend Paolo…
Jul 8, 2024, 18:14 | Insight
Paolo Tarantino: What is HER2 « ultralow » breast cancer, and why should you care?
Paolo Tarantino shared on X: “What is HER2 « ultralow » breast cancer, and why…
Jul 7, 2024, 15:07 | Blog
Final analysis of TUXEDO-1 for HER2+ MBC
Kathrin Dvir, Chief Fellow Hematology-Oncology at Dana-Farber Cancer Institute, shared a post  by Paolo Tarantino, on…
Jul 5, 2024, 06:54 | Blog
Paolo Tarantino: Nearly 1000 downloads in less than a week for our ATEMPT 5-year publication
Paolo Tarantino, posted on X: "Nearly 1000 downloads in less than a week for our…
Jul 3, 2024, 22:59 | Blog
Aleix Prat: Our 2 articles published this week
Aleix Prat, Head of the Medical Oncology Department at Hospital Clínic Barcelona, shared on X:…
Jul 3, 2024, 08:52 | Insight
Paolo Tarantino: More data supporting that ADCs act in part by extending the half life of payloads
Paolo Tarantino shared a post by Raffaele Colombo on X, adding the following: “More data…
Jul 3, 2024, 01:37 | Blog
Albert Grinshpun: Another important sub-population which might enjoy life without chemo
Albert Grinshpun, Goldfarb Advanced Breast Cancer Fellow at the Breast Oncology Center of Dana-Farber Cancer…
Jul 3, 2024, 01:24 | Blog
Paolo Tarantino: ATEMPT would have not been possible without the vision of Sara Tolaney
Sara Tolaney shared a post by Paolo Tarantino on X: “Very lucky to get to…
Jul 2, 2024, 08:37 | Insight
How will we treat breast cancer 10 years from now?
Paolo Tarantino shared an article by Mattea Reinisch et al. on LinkedIn:       …
Jul 2, 2024, 04:25 | OncoDaily Pulse
OncoDaily Party and Yvonne Award 2024 Photos - Part 2
On May 31st, 2024, during the ASCO Annual Meeting in Chicago, OncoDaily hosted the inaugural…
Jul 1, 2024, 18:24 | Insight
Paolo Tarantino: How long should adjuvant T-DM1 be given for stage I HER2+ eBC?
Paolo Tarantino shared on X: "For how long should adjuvant T-DM1 be given for stage…
Jul 1, 2024, 15:23 | Insight
Paolo Tarantino: Final analysis of the ATEMPT phase 2 trial
Paolo Tarantino shared a post on X: “Can ADCs help prevent recurrence from breast cancer…
Jun 30, 2024, 10:58 | Insight
Eleonora Nicolò: Our analysis on safety and efficacy of new drugs investigated in phase I/II clinical trials by age
Eleonora Nicolò, Research Fellow at Weill Cornell Medicine, shared a post on X: "Just out…
Jun 27, 2024, 11:10 | Blog
Press release from the PRESERVE 2 phase 3 trial
Paolo Tarantino shared a post on X: “Press release from the PRESERVE 2 phase 3…
Jun 26, 2024, 15:22 | Insight
Results from the NIAGARA Phase III trial
AztraZeneca released the results of the NIAGARA phase III trial, where INFINZI (durvalumab) showed EFS…
Jun 26, 2024, 07:39 | Insight
Paolo Tarantino discusses ASCO24 Breast Cancer highlights
Sameh AbdelMalak, Director of Oncology at Educational Partnerships at VuMedi, shared on X: "Check out…
Jun 26, 2024, 03:41 | Insight
Paolo Tarantino: Opportunities to improve outcomes for early recurrent TNBC
Paolo Tarantino shared a post on X:         .  "Early recurrent TNBC (Triple-Negative…
Jun 26, 2024, 03:18 | Insight
Paolo Tarantino: The 5 S rules help memorizing a simple framework to manage ILD
Paolo Tarantino shared on LinkedIn: “T-DXd is rapidly expanding in indications, from HER2+, to HER2-low, and…
Jun 25, 2024, 16:01 | Insight
Paolo Tarantino: Phase 1 trial of the HER2 topo1 ADC SHR-A1811 out in Journal of Clinical Oncology
Paolo Tarantino shared on X:  . "Phase 1 trial of the HER2 topo1 ADC SHR-A1811…
Jun 23, 2024, 13:08 | Drugs
Capivasertib is now approved in EU for HR+/HER2- breast cancer
Paolo Tarantino shared a post on X: "Capivasertib is now approved in EU for the…
Jun 22, 2024, 00:42 | Blog
Results from AMEERA-5 published in Journal of Clinical Oncology
Paolo Tarantino shared a post on X: "Results from AMEERA-5 published in Journal of Clinical Oncology.…
Jun 21, 2024, 12:28 | Insight
Paolo Tarantino: The CAPItello290 trial did not meet the dual primary endpoints
Paolo Tarantino shared on X/Twitter: "Press Release: the CAPItello290 trial of 1L paclitaxel +/- capivasertib in…
Jun 21, 2024, 11:16 | Insight
Paolo Tarantino: Phase 1 trial of the MMAF-based, HER2-targeting ADC FS-1502 published in Nature Communications
Paolo Tarantino shared on X/Twitter: "Phase 1 trial of the MMAF-based, HER2-targeting ADC FS-1502 published…
Jun 13, 2024, 07:01 | Blog
Cancer Network - Neil Iyengar and Paolo Tarantino will co-host an X Spaces focused on breast cancer
Cancer Network shared a post on X: "Mark your calendars, in 2 days Neil Iyengar and…
Jun 12, 2024, 15:37 | Societies
Giuseppe Curigliano has been appointed as the President Elect of ESMO
The European Society for Medical Oncology (ESMO) has announced the results of its presidential election.…
Jun 12, 2024, 03:50 | Blog
The most recent Breast Cancer Research Digest by Dana-Farber's Breast Oncology Center
Paolo Tarantino shared a post by Dana-Farber's Breast Oncology Center on X, adding the following: “Latest…
Jun 10, 2024, 16:01 | Blog
Paolo Tarantino: Some thoughts on postMONARCH
Paolo Tarantino shared a post on X: "Some thoughts on postMONARCH - HR often provide a…
Jun 10, 2024, 05:58 | Blog
Paolo Tarantino: Feeling very lucky to be part of this international network of young oncologists
Paolo Tarantino shared a post on X: “Feeling very lucky to be part of this international…
Jun 10, 2024, 02:20 | Blog
Paolo Tarantino: Great to welcome Dr. Abeid Athman for a fellowship at Dana-Farber’s Breast Oncology Center!
Paolo Tarantino shared a post on X: “Great to welcome Dr. Abeid Athman from Kenya for…
Jun 8, 2024, 03:53 | Societies
25 Posts From ASCO24 You Should Not Miss!
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 31st…
Jun 7, 2024, 11:07 | Blog
Paolo Tarantino: Grateful to be part of the ESMO Open team
Paolo Tarantino shared a post by Giuseppe Curigliano on LinkedIn: "Grateful to be part of the…
Jun 7, 2024, 04:51 | Blog
Paolo Tarantino: DB06 showed relevant activity with T-DXd for MBC
Paolo Tarantino shared a post on X: "DB06 showed relevant activity with T-DXd for the 1L…
Jun 6, 2024, 02:15 | Blog
Paolo Tarantino: Rebecca Shatsky presents the Dato/durva module of I-SPY2.2
Paolo Tarantino shared on X/Twitter: "Rebecca Shatsky presents the Dato/durva module of I-SPY2.2. Neoadjuvant Dato-DXd/durva showed…
Jun 6, 2024, 00:29 | Blog
Paolo Tarantino: Expansion cohorts from TBCRC by Nadine Tung
Paolo Tarantino shared a post on X: “One of the most important presentations of ASCO24:…
Jun 5, 2024, 15:09 | Societies
15 Posts From ASCO24 Day 5 You Should Not Miss!
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 31st…
Jun 1, 2024, 23:36 | Blog
Paolo Tarantino: Our article on Optimizing the Safety of ADCs for their Outlook on Cancer treatment has been published in Nature
Paolo Tarantino shared a post on LinkedIn: ''Grateful to Nature for selecting our article on…
Jun 1, 2024, 14:46 | Societies
15 Posts From ASCO24 Day 1 You Should Not Miss!
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is being held from May…
Jun 1, 2024, 08:47 | Blog
Paolo Tarantino: ADCs keep shortening the distance between oncology fields
Paolo Tarantino shared a post on X: "ADCs keep shortening the distance between oncology fields.…
May 31, 2024, 15:41 | Societies
Paolo Tarantino: More than 25 ASCO24 oral presentations by Dana-Farber Cancer Institute researchers
Paolo Tarantino shared a post by Dana-Farber Cancer Institute on X: "More than 25 ASCO24…
May 29, 2024, 08:20 | Blog
Paolo Tarantino: In this work by the AZ translational team, QCS proved superior to manual IHC in predicting the activity of T-DXd
Paolo Tarantino shared a post on X: "In the ph1 trial of T-DXd in HER2-low MBC,…
May 28, 2024, 14:34 | Drugs
Paolo Tarantino: Impressive activity with tucatinib plus trastuzumab for HER2-mutated breast cancer
Paolo Tarantino shared on X: "Impressive activity with tucatinib plus trastuzumab for HER2-mutated breast cancer.…
May 27, 2024, 06:30 | Blog
Paolo Tarantino: The Terri Brodeur Foundation Annual Meeting
Paolo Tarantino shared a post on LinkedIn: ''Just back from the Terri Brodeur Foundation Annual…
May 26, 2024, 08:25 | Blog
Paolo Tarantino: Looking forward to presenting this analysis of T-DXd in 1500 patients with MBC
Paolo Tarantino shared a post by Yakup Ergün, Medical Oncologist at Ankara Numune Training and Research Hospital,…
May 26, 2024, 06:49 | Societies
Paolo Tarantino: Less than a week to what promises to be a terrific ASCO24
Paolo Tarantino recently shared a post on X: "Less than a week to what promises…
May 25, 2024, 15:15 | Blog
Paolo Tarantino: I’m extremely excited to support Giuseppe Curigliano for the next ESMO Presidential Elections
Paolo Tarantino shared on LinkedIn: "I’m extremely excited to support Giuseppe Curigliano for the next ESMO…
May 25, 2024, 07:41 | Insight
Paolo Tarantino: I’m extremely excited to support Giuseppe Curigliano for the next ESMO Presidential Elections!
Paolo Tarantino shared on LinkedIn: “I’m extremely excited to support Giuseppe Curigliano for the next…
May 23, 2024, 11:03 | Blog
Join the ultimate face-off between Paolo Tarantino and Aakash Desai as they review the latest in breast and thoracic oncology!
Paolo Tarantino shared on X: "Exciting news from ASCO24! Join the ultimate face-off between Paolo…
May 23, 2024, 11:01 | Insight
Paolo Tarantino: More than 10,000 downloads for our editorial on the “5 S rules” to manage ILD
Paolo Tarantino shared on X: "More than 10,000 downloads for our editorial on the “5…
May 22, 2024, 09:09 | Blog
Paolo Tarantino: Mark your calendars for PER’s 6th Annual Precision Medicine Symposium
Paolo Tarantino made the following post on X: “Mark your calendars for PER’s 6th Annual Precision…
May 22, 2024, 04:28 | Blog
Michael Torres: This review is getting a lot of play
Michael Torres, PhD in Cancer Bio at UT Southwestern News, shared on X/Twitter: "Homogeneous multi-payload…
May 20, 2024, 15:03 | Blog
Paolo Tarantino: Great recap of the randomized trials in the 2L+ HR+ MBC setting by Eva M Ciruelos
Paolo Tarantino shared on X/Twitter: "Great recap of the randomized trials in the 2L+ HR+ MBC…
May 20, 2024, 13:27 | Blog
Paolo Tarantino: A true honor to join the Executive Scientific Committee of the ENA Triple Meeting 2024
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn…
May 18, 2024, 14:00 | Blog
Paolo Tarantino: Very promising activity with a new CDK4i
Paolo Tarantino shared the following post by ESMO on X, adding the following: "Very promising…
May 18, 2024, 11:16 | Blog
Paolo Tarantino: Important point by Erika Hamilton - common questions should derive from RCTs
Paolo Tarantino shared the following post by ESMO on X, adding the following: "Important point…
May 18, 2024, 09:54 | Societies
Paolo Tarantino: Why was IMpassion132 negative?
Daniel Stover, Medical Oncologist and Computational Biologist at Ohio State University Comprehensive Cancer Center, shared…
May 18, 2024, 08:31 | Opinion
Guillermo Villacampa: Marleen Kok presents the ESMO Breast 24 key message in translation research
Paolo Tarantino shared the following post by Guillermo Villacampa, Biostatistician in the Oncology Data Science…
May 18, 2024, 08:12 | Blog
Paolo Tarantino: Sara Tolaney recapitulating 10+ years of de-escalation trials
Paolo Tarantino shared a post on X/Twitter: ''Terrific presentation by Sara Tolaney at ESMO Breast24, recapitulating…
May 18, 2024, 02:12 | Blog
Paolo Tarantino: Important subanalysis of SOFT/TEXT presented by Otto Metzger
Paolo Tarantino shared on X: "Important subanalysis of SOFT/TEXT presented by Otto Metzger from Dana-Farber’s…
May 16, 2024, 14:13 | Opinion
Paolo Tarantino: A tremendous opportunity to validate the potential of HER2DX to predict outcomes in HER2+ BC
Paolo Tarantino made the following post on X: “HER2DX to Be Validated in Pivotal ECOG-ACRIN CompassHER2…
May 16, 2024, 11:06 | Societies
Stephanie Graff: Chairs kick off ESMOBreast24
Paolo Tarantino shared a post by Stephanie Graff on X, adding: . "Impressive continuous growth…
May 15, 2024, 12:48 | Opinion
Paolo Tarantino: Honored to serve as Ambassador for ESMOBreast24!
Paolo Tarantino shared a post  by ESMO, on LinkedIn: "Honored to join this outstanding group and…
May 15, 2024, 04:35 | Blog
Paolo Tarantino: A pleasure to co-host the latest ESMO Open podcast with Giuseppe Curigliano
Paolo Tarantino shared a post by ESMO - European Society for Medical Oncology on LinkedIn, adding:…
May 14, 2024, 03:26 | Blog
Top 10 Abstracts at ESMO Breast 24 by Paolo Tarantino
Paolo Tarantino made the following post on LinkedIn: "Less than 48h to ESMO Breast 24:…
May 14, 2024, 03:07 | Blog
Erika Hamilton: Fantastic list for ESMO Breast 24
Erika Hamilton shared a post by Paolo Tarantino on LinkedIn, adding: "Fantastic list for ESMO Breast 24.…
May 13, 2024, 12:54 | Blog
Become part of the conversation about the science presented at ESMO Breast24
European Society for Medical Oncology shared on their X page: "Do not miss the latest…
May 13, 2024, 07:12 | Blog
Paolo Tarantino: DESTINY-Breast06 will be presented on 6/2 at ASCO24 by my friend and mentor of many years Giuseppe Curigliano
Paolo Tarantino shared on X: "DESTINY-Breast06 will be presented on 6/2 at ASCO24 by my…
All: 201 Posts: 1 - 100
Special Coverage